0001735726-21-000001.txt : 20210326 0001735726-21-000001.hdr.sgml : 20210326 20210326172239 ACCESSION NUMBER: 0001735726-21-000001 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210326 DATE AS OF CHANGE: 20210326 EFFECTIVENESS DATE: 20210326 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OncoNano Medicine, Inc. CENTRAL INDEX KEY: 0001735726 IRS NUMBER: 811713330 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-378478 FILM NUMBER: 21778588 BUSINESS ADDRESS: STREET 1: 550 RESERVE STREET STREET 2: SUITE 190 CITY: SOUTHLAKE STATE: TX ZIP: 76092 BUSINESS PHONE: (682) 712-1581 MAIL ADDRESS: STREET 1: 550 RESERVE STREET STREET 2: SUITE 190 CITY: SOUTHLAKE STATE: TX ZIP: 76092 D/A 1 primary_doc.xml X0708 D/A LIVE 0001735726 OncoNano Medicine, Inc. 181 Grand Avenue Suite 225 Southlake TX TEXAS 76092 682.285.1411 DELAWARE None None Corporation true Martin Driscoll c/o OncoNano Medicine, Inc. 181 Grand Avenue, Suite 225 Southlake TX TEXAS 76092 Executive Officer Director John Dyett c/o OncoNano Medicine, Inc. 181 Grand Avenue, Suite 225 Southlake TX TEXAS 76092 Director Alvaro Guillem c/o OncoNano Medicine, Inc. 181 Grand Avenue, Suite 225 Southlake TX TEXAS 76092 Director Joydeep Goswami c/o OncoNano Medicine, Inc. 181 Grand Avenue, Suite 225 Southlake TX TEXAS 76092 Director Matthew Head c/o OncoNano Medicine, Inc. 181 Grand Avenue, Suite 225 Southlake TX TEXAS 76092 Executive Officer Caleb Smith c/o OncoNano Medicine, Inc. 181 Grand Avenue, Suite 225 Southlake TX TEXAS 76092 Director Biotechnology Decline to Disclose 06b true 0001735726-20-000001 2020-10-15 false true false 0 Salem Partners LLC 43363 None None 11111 Santa Monica Blvd., Suite 2250 Los Angeles CA CALIFORNIA 90025 OR OREGON TX TEXAS IN INDIANA FL FLORIDA NV NEVADA NY NEW YORK CO COLORADO PA PENNSYLVANIA MA MASSACHUSETTS NC NORTH CAROLINA AZ ARIZONA NJ NEW JERSEY CA CALIFORNIA false 60000000 26425222 33574778 false 24 0 1321261 true The broker earned $1,321,261 in cash and will earn a (1) 5.0% cash fee on any later sales and (2) warrant to purchase shares of common stock equal to 4.0% of the number of shares sold in the aggregate transaction. 0 false OncoNano Medicine, Inc. /s/ Martin Driscoll Martin Driscoll CEO 2021-03-26